Janux Therapeutics (JANX) Other Non-Current Assets (2021 - 2026)
Janux Therapeutics (JANX) posted quarterly Other Non-Current Assets of $3.9 million for Q1 2026, up 41.26% year-over-year from $2.8 million in Q1 2025, and up 383.33% quarter-over-quarter from $816000.0 in Q4 2025.
Janux Therapeutics (JANX) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Other Non-Current Assets for 6 consecutive years, with $3.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 41.26% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $3.9 million (up 41.26% YoY), while the FY2025 annual figure was $816000.0, changed 0.0% from the prior year.
- Other Non-Current Assets advanced to $3.9 million in Q1 2026 per JANX's latest filing, from $816000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $3.9 million in Q1 2026 and bottomed at $816000.0 in Q1 2022.
- Historically, Other Non-Current Assets has averaged $1.6 million across 5 years, with a median of $816000.0 in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 482.86% — and 2024, when it plunged 67.48%.
- Janux Therapeutics' Other Non-Current Assets stood at $816000.0 in 2022, then surged by 207.48% to $2.5 million in 2023, then slumped by 67.48% to $816000.0 in 2024, then changed by 0.0% to $816000.0 in 2025, then jumped by 383.33% to $3.9 million in 2026.
- Business Quant data shows JANX's Other Non-Current Assets at $3.9 million in Q1 2026, $816000.0 in Q4 2025, and $816000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | 2.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.91 Mn |
| Mar 31, 2026 | 3.94 Mn |
| Dec 31, 2025 | 816,000.00 |
| Sep 30, 2025 | 816,000.00 |
| Jun 30, 2025 | 2.69 Mn |
| Mar 31, 2025 | 2.79 Mn |
| Dec 31, 2024 | 816,000.00 |
| Sep 30, 2024 | 816,000.00 |
| Jun 30, 2024 | 816,000.00 |
| Mar 31, 2024 | 2.52 Mn |
| Dec 31, 2023 | 2.51 Mn |
| Sep 30, 2023 | 816,000.00 |
| Jun 30, 2023 | 2.43 Mn |
| Mar 31, 2023 | 1.61 Mn |
| Dec 31, 2022 | 816,000.00 |
| Sep 30, 2022 | 816,000.00 |
| Jun 30, 2022 | 816,000.00 |
| Mar 31, 2022 | 816,000.00 |
| Dec 31, 2021 | 392,000.00 |
| Sep 30, 2021 | 140,000.00 |